Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 608 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 608 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $73,422.08. Following the completion of the transaction, the chief financial officer now directly owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The shares were sold at an average price of $119.09, for a total value of $59,068.64.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total value of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total value of $127,229.26.
• On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total value of $72,650.10.

Natera Stock Down 1.1 %

NTRA opened at $118.65 on Thursday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock has a market cap of $14.57 billion, a P/E ratio of -38.03 and a beta of 1.53. The stock’s 50 day moving average price is $123.43 and its 200 day moving average price is $111.03.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. During the same period last year, the firm earned ($0.97) EPS. The firm’s revenue for the quarter was up 58.1% on a year-over-year basis. As a group, research analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on NTRA shares. Piper Sandler reissued an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. TD Cowen increased their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Morgan Stanley increased their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, UBS Group reduced their target price on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Hedge Funds Weigh In On Natera

Several hedge funds have recently modified their holdings of NTRA. Itau Unibanco Holding S.A. acquired a new position in shares of Natera during the 2nd quarter valued at $28,000. Quarry LP increased its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the last quarter. Tobam acquired a new position in shares of Natera in the 2nd quarter worth $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Natera in the 1st quarter worth $83,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.